



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 25, 2024

Linda Rubinstein  
Chief Financial Officer  
Adverum Biotechnologies, Inc.  
100 Cardinal Way  
Redwood City , CA

**Re: Adverum Biotechnologies, Inc.**  
**Form 10-K for Fiscal Year Ended December 31, 2022**  
**Filed March 30, 2023**  
**File No. 001-36579**

Dear Linda Rubinstein:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences